Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development

Set Alert for Research & Development

Cytokinetics’ Failure In ALS Clears Way For Focus On Aficamten

With a data monitoring committee finding no signs of efficacy in a Phase III trial of ALS candidate reldesemtiv, Cytokinetics can conserve cash and center on aficamten for hypertrophic cardiomyopathy.

Clinical Trials Business Strategies

The 2023 Scrip Awards Is Now Open For Entries

Entries for the Scrip Awards are now open. Now in their 19th year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health.

Commercial Research & Development

EIP And Diffusion Combine To Form CNS Firm With Dementia Focus

The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.

M & A Neurology

Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’

Senior VPs from Novartis and Novo Nordisk offered suggestions ranging from protecting IP and fixing the perception of “elephants roaming the streets,” to “fit for purpose” global development plans to improve the research landscape in India, during a recent webinar, which also saw academia weighing in on various issues.

Research & Development India

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.

Emerging Company Profile Companies

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Blood & Coagulation Disorders Gene Therapy

Roche Continues To Cast Its Collaborations Net Wide

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.

Deals Business Strategies

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.

Sales & Earnings Renal

FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves

The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. Other CDK2 inhibitors have had ocular toxicity issues as well.

Cancer Clinical Trials

J&J Quits RSV Development With Two Rivals Already Poised For US Approval

The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.

Business Strategies Clinical Trials

Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion

The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.

Scrip Asks Diversity & Inclusion

Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals

Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.

Business Strategies Clinical Trials
UsernamePublicRestriction

Register